Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 20/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12439422 | 0.96 | IGF1R (0.66) | IGF1R | |
| SCHEMBL12439767 | 0.91 | IGF1R (0.58) | IGF1R | |
| SCHEMBL11343710 | 0.91 | IGF1R (0.67) | IGF1R | |
| SCHEMBL11938922 | 0.90 | IGF1R (0.58) | IGF1R | |
| SCHEMBL12439789 | 0.89 | IGF1R (0.56) | IGF1R | |
| SCHEMBL11343860 | 0.89 | IGF1R (0.70) | IGF1R | |
| SCHEMBL11341456 | 0.88 | IGF1R (0.70) | IGF1R | |
| SCHEMBL12438426 | 0.88 | IGF1R (0.58) | IGF1R | |
| SCHEMBL11938857 | 0.88 | IGF1R (0.56) | IGF1R | |
| SCHEMBL11343872 | 0.88 | IGF1R (0.69) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139483-B9 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2139483-B1 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-1841760-B1 | PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2011-08-10 | — | — | EP | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008005538-A2 | METHODS OF USING IGF1R AND ABL KINASE MODULATORS | EXELIXIS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |